0001127602-21-014113.txt : 20210420 0001127602-21-014113.hdr.sgml : 20210420 20210420160936 ACCESSION NUMBER: 0001127602-21-014113 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210419 FILED AS OF DATE: 20210420 DATE AS OF CHANGE: 20210420 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zaks Tal Zvi CENTRAL INDEX KEY: 0001690927 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 21837938 MAIL ADDRESS: STREET 1: C/O ADAPTIMMUNE THERAPEUTICS PLC STREET 2: 60 JUBILEE AVE, MILTON PARK CITY: ABINGDON, OXFORDSHIRE STATE: X0 ZIP: OX14 4RX ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2021-04-19 0001682852 Moderna, Inc. MRNA 0001690927 Zaks Tal Zvi C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 Chief Medical Officer Common Stock 2021-04-19 4 M 0 5000 12.21 A 5000 D Common Stock 2021-04-19 4 S 0 656 160.48 D 4344 D Common Stock 2021-04-19 4 S 0 1332 161.62 D 3012 D Common Stock 2021-04-19 4 S 0 1250 162.65 D 1762 D Common Stock 2021-04-19 4 S 0 500 163.89 D 1262 D Common Stock 2021-04-19 4 S 0 462 165.04 D 800 D Common Stock 2021-04-19 4 S 0 700 166.31 D 100 D Common Stock 2021-04-19 4 S 0 100 167.56 D 0 D Stock Option (Right to Buy) 12.21 2021-04-19 4 M 0 5000 0 D 2027-10-03 Common Stock 5000 151282 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.04 to $160.88. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.14 to $162.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.22 to $163.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.50 to $164.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.71 to $165.36. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $166.07 to $166.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). /s/ Brian Sandstrom, as Attorney-in-Fact 2021-04-20